| Literature DB >> 28748002 |
Hugo Sanchez1, Mohammad B Hossain2, Lydia Lera1, Sandra Hirsch3, Cecilia Albala1, Ricardo Uauy1, Karin Broberg2,4, Ana M Ronco3.
Abstract
BACKGROUND: Changes in DNA methylation, one of the most studied epigenetic mechanisms, are considered an initial marker for early cancer detection. We evaluated how availability of dietary factors (folates and vitamin B12) involved in one-carbon metabolism may contribute to DNA methylation changes of cancer-related genes in human subjects.Entities:
Keywords: DNA methylation; Folates; Tumor suppressor genes
Mesh:
Substances:
Year: 2017 PMID: 28748002 PMCID: PMC5525256 DOI: 10.1186/s13148-017-0374-y
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Fig. 1Pyrosequencing amplicons of p16, MLH1, and MGMT relative to known landmarks, including transcription start sites (TSS)
Characteristics of subjects
| Men | Women | Total | |
|---|---|---|---|
| Age (years)a | |||
| mean ± SD | 73.5 ± 2.7 | 73.9 ± 3.1 | 73.8 ± 3.0 |
| 95% CI | 72.9–74.1 | 73.5–74.4 | 73.4–74.2 |
| Education (years) | |||
| median (p25–p75)b | 6 (4–8) | 6 (8–3) | 6 (8–3) |
| ≤6 years % ( | 56.6 (43) | 63.7 (107) | 61.5 (150) |
| 95% CI | 44.7–67.9 | 55.9–71.0 | 55.1–67.6 |
| Medication (number)***c | |||
| 0, % ( | 23.4 (18) | 11.1 (19) | 14.9 (37) |
| 95% CI | 14.5–34.4 | 6.8–16.7 | 10.7–19.9 |
| 1, % ( | 19.5 (15) | 10.5 (18) | 13.3 (33) |
| 95% CI | 11.3–30.1 | 6.3–16.0 | 9.3–18.1 |
| 2–3, % ( | 36.4 (28) | 34.9 (60) | 35.3 (88) |
| 95% CI | 25.7–48.1 | 27.8–42.5 | 29.4–41.6 |
| 4+, % ( | 20.8 (16) | 43.6 (75) | 36.6 (91) |
| 95% CI | 12.4–31.5 | 36.1–51.4 | 30.5–42.9 |
| MMSE*b | |||
| median (p25–p75) | 28 (26–29) | 27 (25–29) | 27 (25–29) |
| BMI*a | |||
| BMI*a mean ± SD | 26.9 ± 3.2 | 28.5 ± 5.1 | 28.1 ± 4.7 |
| 95% CI | 26.2–27. 7 | 27.7–29.3 | 27.4–28.6 |
| Tobacco consumption**c | |||
| % ( | 10.5 (8) | 5.8 (10) | 7.3 (18) |
| CI 95% | 4.6–19.4 | 2.8–10.4 | 4.3–11.2 |
Medications frequently used in elderly: antihypertensive, anti-inflammatory, antidepressant
BMI Body Mass Index, MMSE Minimental state examination
*p < 0.05; **p < 0.01; ***p < 0.001
aTwo-sample mean-comparison test
bTwo-sample Wilcoxon rank-sum test
cPearson’s Chi2 test
DNA methylation in specific CpG sites
| Genes | CpG site | Men ( | Women ( | Total ( |
|---|---|---|---|---|
|
| 1 | 86.2 (84.5–86.9) | 85.75 (84.5–86.9) | 85.8 (84.8–86.7) |
| 2 | 82.6 (82.3–82.8) | 82.5 (82.2–82.8) | 82.5 (82.3–82.7) | |
| 3 | 80.875 (80.4–81.75) | 80.9 (80.3–81.3) | 80.9 (80.5–81.2) | |
| 4 | 82.2 (81.3–83.2) | 82.0 (81.6–82.4) | 82.0 (81.7–82.4) | |
| Average | 83.3 (82.8–83.8) | 82.8 (82.6–83.3) | 82.9 (82.65–83.4) | |
|
| 1 | 3.36 (3.0–3.89) | 3.46 (3.25–3.64) | 3.44 (3.25–3.6) |
| 2 | 1.575 (1.16–1.9) | 1.58 (1.45–1.87) | 1.58 (1.46–1.79) | |
| 3 | 1.88 (1.37–2.12) | 1.84 (1.62–2.07) | 1.85 (1.66–2.04) | |
| 4* | 2.2 (1.91–2.25) | 1.88 (1.75–2.05) | 1.96 (1.82–2.11) | |
| 5 | 0.91 (0–1.60) | 1.65 (1.41–1.92) | 1.49 (1.34–1.77) | |
| 6 | 0 | 0 | 0 | |
| 7 | 1.89 (1.38–2.23) | 1.94 (1.73–2.12) | 1.91 (1.71–2.09) | |
| Average | 1.89 (1.66–2.06) | 1.92 (1.78–2.02) | 1.907 (1.79–2.01) | |
|
| 1 | 0 (0–0.99) | 0 | 0 |
| 2 | 1.39 (0–2.35) | 1.82 (0–2.10) | 1.725 (0–2.07) | |
| 3 | 0 | 0 | 0 | |
| 4γ | 2.3 (1.75–2.80) | 2.495 (1.96–2.84) | 2.435 (1.97–2.77) | |
| Average | 1.25 (0.70–1.38) | 1.12 (0.74–1.31) | 1.165 (0.81–1.31) | |
|
| 1 | 3.345 (2.53–4.21) | 4.01 (3.51–4.66) | 3.8 (3.41–4.26) |
| 2 | 0 (0–1.65) | 0 (0–1.88) | 0 | |
| 3 | 0 | 0 | 0 | |
| 4 | 1.865 (1.38–2.31) | 1.87 (1.61–2.26) | 1.87 (1.61–2.15) | |
| 5 | 0 | 0 | 0 | |
| 6 | 0 | 0 | 0 | |
| Average | 1.555 (1.10–2.11) | 1.72 (1.39–1.87) | 1.66 (1.44–1.87) |
Results are expressed as percentages of methylation and 95% CI. Two-sample Wilcoxon rank-sum test *p = 0.04; γ p = 0.07; for other results p > 0.1
Blood level of vitamins and metabolites
| Men | Women | Total | |
|---|---|---|---|
| Vitamin B12 (pmol/L) Median | 370.7 | 438.5 | 409.3 |
| <148 pmol/L % ( | 10.6(7) | 11.3(16) | 11.1(23) |
| 148–221 pmol/L % ( | 12.1(8) | 9.9(14) | 10.6(22) |
| >221 pmol/L % ( | 77.3(51) | 78.9(112) | 78.4(163) |
| MMA (nmol/L) Median | 187 | 177.5 | 180 |
| HoloTC (pmol/L) Median | 67.7 | 102.9** | 180 |
| Folates (nmol/L) Median | 34.6 | 36.6* | 36 |
| >45.3 nmol/L % ( | 24.3(18) | 34.1(57)γ
| 31.1(75) |
| Homocysteine (μmol/L) Median | 11.3 | 10.6 | 10.8 |
Results are expressed as median (p25–p75) and % (n) and 95% CI
MMA methylmalonic acid, HoloTC holotranscobalamin
*p = 0.0499, two-sample Wilcoxon rank sum test; **p = 0.029; γ p = 0.031, Chi2 test
Spearman correlation for blood concentrations of vitamins and metabolites and DNA methylation in specific CpG sites of LINE-1, p16, MLH1, and MGMT genes
| CpG site | Vit B12 | Folates | HoloTC | Hcy | MMA | |
|---|---|---|---|---|---|---|
|
| 1 | −0.1064 | 0.0193 | −0.1357 | 0.0509 | 0.0298 |
| 2 | −0.0106 | −0.1259 | −0.0680 | −0.0811 | 0.1004 | |
| 3 | 0.1067 | 0.0360 | 0.1321 | −0.0644 | −0.0318 | |
| 4 | −0.0346 | −0.0127 | −0.1313 | 0.0281 | 0.0394 | |
| Average | −0.0373 | 0.0302 | −0.1135 | 0.0604 | 0.0166 | |
|
| 1 | 0.1888* | 0.0156 | 0.1152 | −0.0002 | −0.0137 |
| 2 | −0.0552 | −0.1519 | 0.0104 | −0.0239 | −0.0303 | |
| 3 | 0.2965* | 0.2320* | 0.1137 | −0.1293 | −0.1288 | |
| 5 | 0.2198* | 0.2974* | 0.0595 | −0.0462 | −0.1619 | |
| 6 | −0.1668 | −0.1787 | −0.0167 | 0.0709 | 0.0449 | |
| 7 | 0.0863 | −0.1029 | 0.1230 | 0.0455 | −0.0597 | |
| Average | 0.2288* | 0.0867 | 0.1553 | −0.0880 | −0.1318 | |
|
| 1 | −0.2809* | −0.1616 | 0.0360 | −0.0555 | −0.0634 |
| 2 | 0.0977 | 0.2453* | −0.0248 | −0.0422 | −0.0656 | |
| 3 | −0.1404 | −0.1102 | −0.0374 | −0.0393 | −0.0451 | |
| 4 | 0.1246 | 0.3121* | 0.0399 | −0.1387 | −0.1486 | |
| Average | −0.1081 | 0.1786* | 0.0188 | −0.1410 | −0.1478 | |
|
| 1 | 0.1118 | 0.2291* | −0.0167 | −0.0589 | −0.0211 |
| 2 | 0.3142* | 0.4196* | −0.0082 | −0.0702 | −0.1504 | |
| 3 | 0.0791 | 0.2007* | −0.0522 | −0.0417 | −0.0876 | |
| 4 | −0.1561 | −0.3457* | 0.0002 | 0.0808 | 0.1207 | |
| 5 | −0.1187 | −0.1011 | −0.0570 | −0.0621 | −0.0806 | |
| 6 | −0.0111 | −0.0272 | −0.0012 | −0.1773 | −0.1511 | |
| Average | 0.1168 | 0.2489* | −0.0591 | −0.0567 | −0.0474 |
*p < 0.01
Logistic Regression Model between vitamin B12 and folate levels and the risk of methylation of p16, MLH1, and MGMT at the 3rd tertile (%)
| Vit B12 (pmol/L) | Folates* (nmol/L) | |||||
|---|---|---|---|---|---|---|
| <148 | 148–221 | >45.3 | ||||
|
| CpG | 3a | OR | 0.70 | 0.36 | 1.97 |
| 95% CI | 0.23–2.08 | 0.10–1.23 | 1.04–3.75 | |||
| 5b | OR | 0.46 | 0.67 | 4.17 | ||
| 95% CI | 0.13–1.6 | 0.2–2.2 | 2.12–8.19 | |||
|
| 1c | OR | 0.56 | 0.93 | 2.31 | |
| 95% CI | 0.14–2.19 | 0.28–3.13 | 1.15–4.64 | |||
| 2d | OR | 0.43 | 0.86 | 3.73 | ||
| 95% CI | 0.10–1.88 | 0.26–2.90 | 1.83–7.59 | |||
| 3e | OR | 1.18 | 1.22 | 2.08 | ||
| 95% CI | 0.34–4.13 | 0.38–3.95 | 1.03–4.20 | |||
| Averagef | OR | 0.99 | 1.60 | 2.20 | ||
| 95% CI | 0.26–3.80 | 0.48–5.32 | 1.08–4.50 | |||
|
| 4g | OR | 0.96 | 0.12 | 3.91 | |
| 95% CI | 0.28–3.26 | 0.014–0.99 | 1.88–8.11 | |||
| Averageh | OR | 0.92 | 0.6 | 2.84 | ||
| 95% CI | 0.28–2.98 | 0.19–2.52 | 1.42–5.69 | |||
Adjusted by sex, age, tobacco, BMI, Hcy, HoloTC, and MMA
OR odd ratio, CI confidence interval
*p < 0.05 vs folate <45.3 nmol/L
a< 2.35% methylation
b2.11% methylation
c< 5.24% methylation
d< 2.65% methylation
e < 0.34% methylation
f< 2.14% methylation
g< 3.2% methylation
h< 1.48% methylation